In the first part of an NBC News investigation that we reposted about the BARD G2 series blood clot filter,it was revealed that the device, which is implanted in thousands of people, was found to be associated with 27 deaths and hundreds of other non-fatal problems after it received FDA clearance. NBC followed up with more details revolving the case:
In 2002, medical giant C.R. Bard recruited Kay Fuller, a veteran regulatory specialist, to help secure FDA clearance for its Recovery blood clot filter, after the agency had turned down a previous application.
The Recovery, a one-and-a-half-inch metal trap, was designed to sit inside a major vein, the vena cava, and block blood clots from traveling to the heart or lungs, where they could be deadly.
In an exclusive interview with NBC News, Fuller said that she had serious concerns about the Recovery. A small human clinical trial raised red flags, and the company did not give her important safety performance test results, she said.
But when she voiced her concerns, she said, Bard officials didn’t seem to want to hear them.
“It was basically, you know, if you continue to pursue these questions, that I was going to be asked not to be on the team,” Fuller said. “And I was shocked.”
Fuller says she told her boss she would not sign the application until the issues were resolved. Bard submitted its application to the FDA with what appears to be Fuller’s signature on it.
Above, the signature on C.R. Bard’s FDA application, which Kay Fuller says she did not sign. Below, what Fuller says is her actual signature.
“That’s not my signature,” Fuller told NBC News when shown a copy of the paperwork. A sample of her signature from that time is markedly different from the one on the application.
Was her signature forged?
“I will tell you I did not sign it,” Fuller said, adding that her name was signed on the application without her knowledge.
Fuller said she resigned from Bard, but not before reporting her safety concerns to the FDA. “I never knew what they did after that,” she said.
The FDA won’t say if it acted on Fuller’s tip and denied requests for an interview. In a statement, it said it “takes very seriously” any complaints about “forgeries and device issues.”
Bard executives also declined to be interviewed but said any suggestion the New Jersey-based company submitted forged documents to the FDA is “flatly untrue.”
You can read the full story here.
If you or a loved one has been injured by one of these deadly devices, contact us to day and see if you are entitled for financial compensation.